Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Jennifer Heideman"'
Autor:
Jamey P. Weichert, Lance T. Hall, Scott B. Perlman, Joanne E. Mortimer, Sam J. Lubner, Glenn Liu, Jacqueline A. Mullvain, Michael J. Pishvaian, Katherine Oliver, Jennifer Heideman
Publikováno v:
Cancer Investigation. 33:483-489
This study explores the imaging and therapeutic properties of a novel radiopharmaceutical, (131)I-CLR1404. Phase 1a data demonstrated safety and tumor localization by SPECT-CT. This 1b study assessed safety, imaging characteristics, and possible anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::536a9679ae8a60f783a91f8a88c65263
https://doi.org/10.3109/07357907.2015.1081691
https://doi.org/10.3109/07357907.2015.1081691
Autor:
Kurt Osterby, Jens C. Eickhoff, George Wilding, Glenn Liu, Jill M. Kolesar, Jennifer Heideman, Susan Johnston, Colby A. Cantu, Kari B. Wisinski, Amye J. Tevaarwerk
Publikováno v:
American Journal of Health-System Pharmacy. 72:958-965
Purpose Potential cytochrome P-450 (CYP) drug–drug interactions in adults with metastatic solid tumors and their effect on eligibility for Phase I clinical trials were characterized. Methods This study included adult patients with metastatic solid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::406c90478d07b54009c1a6aa50e028e1
https://doi.org/10.2146/ajhp140591
https://doi.org/10.2146/ajhp140591
Autor:
P Scully, Lakeesha Carmichael, Jill M. Kolesar, Justine Yang Bruce, Scott B. Perlman, Jens C. Eickhoff, Jennifer Heideman, Robert Jeraj, Glenn Liu
Publikováno v:
Cancer Chemotherapy and Pharmacology. 76:187-195
Rapid disease progression associated with increased tumor proliferation has been observed during withdrawal of anti-angiogenic therapy. We characterize the dynamics of withdrawal flare for axitinib.Thirty patients with metastatic solid malignancies r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c030e97d3fb5e4ca3eccb3887e910b
https://doi.org/10.1007/s00280-015-2779-7
https://doi.org/10.1007/s00280-015-2779-7
Autor:
Christopher Flynn, Jill M. Kolesar, Kari B. Wisinski, Moniba Nazeef, Jens C. Eickhoff, Mark E. Burkard, Amye J. Tevaarwerk, Jennifer Heideman, Glenn Liu
Publikováno v:
Cancer Research. 75:P5-19
Background : AKT mediates signaling in the human epidermal growth factor receptor-2 (HER2) pathway. HER2 inhibition can result in feedback regulation of signaling, leading to high AKT activity. Preclinical studies demonstrate activity of combined HER
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10fcedce9d74b545afc2645b3730ac0d
https://doi.org/10.1158/1538-7445.sabcs14-p5-19-20
https://doi.org/10.1158/1538-7445.sabcs14-p5-19-20
Autor:
Jill M. Kolesar, RJ Millholland, Jennifer Heideman, Uchenna O. Njiaju, Amye J. Tevaarwerk, Kari B. Wisinski, LE Poggi, KA Oliver, Jens C. Eickhoff, KR Osterby, SA Johnston
Publikováno v:
Cancer Research. 72:P6-12
Background: In the current era of personalized medicine, oral targeted therapies are increasingly used in cancer treatment. In breast cancer, oral anti-estrogen agents have historically been part of standard treatment for hormone receptor positive di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f40d8e6259014e131b64c898d192bdeb
https://doi.org/10.1158/0008-5472.sabcs12-p6-12-02
https://doi.org/10.1158/0008-5472.sabcs12-p6-12-02
Autor:
Gil Edward Harmon, Murtuza M. Rampurwala, Matt Scarpelli, Jens C. Eickhoff, Lakeesha Carmichael, Jill Kolesar, Kimberly Binger, Jennifer Heideman, Scott Perlman, Chris Liang, Gary Dukart, Robert Jeraj, Glenn Liu, Justine Yang Bruce
Publikováno v:
Journal of Clinical Oncology. 35:e14088-e14088
e14088 Background: Increased tumor proliferation has been observed during withdrawal of anti-angiogenic therapy, known as withdrawal flare, which has been demonstrated using [18-F] fluorothymidine [FLT] PET/CT . Sequencing chemotherapy may increase t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0df709ba258104f689fb9debd6e0e9a
https://doi.org/10.1200/jco.2017.35.15_suppl.e14088
https://doi.org/10.1200/jco.2017.35.15_suppl.e14088
Autor:
Kimberly Binger, Jennifer Heideman, Susan Johnston, Lakeesha Carmichael, Jens C. Eickhoff, Robert Jeraj, Scott B. Perlman, Mark N. Stein, Glenn Liu, Justine Yang Bruce, Jill M. Kolesar, Hans J. Hammers
Publikováno v:
Cancer chemotherapy and pharmacology. 73(3)
Sunitinib treatment results in a compensatory increase in plasma VEGF levels. Acute withdrawal of sunitinib results in a proliferative withdrawal flare, primarily due to elevated VEGF levels. Concurrent sunitinib plus bevacizumab is poorly tolerated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76f8f4bdc68abc2dd6617ea22bf72cab
https://pubmed.ncbi.nlm.nih.gov/24414551
https://pubmed.ncbi.nlm.nih.gov/24414551
Autor:
Jens C. Eickhoff, Jill M. Kolesar, Glenn Liu, Christos Kyriakopoulos, Kari B. Wisinski, Jennifer Heideman
Publikováno v:
Journal of Clinical Oncology. 33:2554-2554
2554 Background: A wide variety of human cancers exhibit dysregulated c-Met activity that has implications in oncogenesis. Phosphorylation of c-Met results in activation of the PI3K/AKT/mTOR pathwa...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f5ad2ee7d344f64958ede1d2e73275a
https://doi.org/10.1200/jco.2015.33.15_suppl.2554
https://doi.org/10.1200/jco.2015.33.15_suppl.2554
Autor:
Kim Harrow, Jill M. Kolesar, Kimberly Binger, Glenn Liu, Jens C. Eickhoff, Murtuza Rampurwala, Lakeesha Carmichael, Chris Liang, Justine Yang Bruce, Scott B. Perlman, Robert Jeraj, Jennifer Heideman, Matthew Scarpelli, Gary Dukart
Publikováno v:
Cancer Chemother Pharmacol
BACKGROUND: A sequential approach, synchronizing cell-cycle specific chemotherapy during VEGFR-TKI treatment breaks, may improve the therapeutic index of this combination therapy. In this study we investigate the safety/tolerability and pharmacodynam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57332446c6622421810c3dc903b1d769
https://doi.org/10.1200/jco.2015.33.15_suppl.tps2601
https://doi.org/10.1200/jco.2015.33.15_suppl.tps2601
Autor:
Robert Jeraj, Scott B. Perlman, Jennifer Heideman, Lakeesha Carmichael, Ludimila Cavalcante, Justine Yang Bruce, Glenn Liu, M Scarpelli
Publikováno v:
Journal of Clinical Oncology. 33:11105-11105
11105 Background: Axitinib (AX) is a potent inhibitor of receptor tyrosine kinases (RTK) of VEGFR-1,2,3. We previously showed that exposure to AX resulted in a decrease in tumor proliferation and v...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8cf486485784e1858c6c067adbbd377
https://doi.org/10.1200/jco.2015.33.15_suppl.11105
https://doi.org/10.1200/jco.2015.33.15_suppl.11105